InsiderTrades.com logo
Strange new buyer driving up gold
From Stansberry Research   |   Ad
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
But there's a much better move you can make to get in front of these big moves today.
John Temperato net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

John Temperato Biography and Net Worth

CEO of 9 Meters Biopharma
Mr. Temperato is an industry veteran with a wealth of gastrointestinal (GI) focused experience in both the operational and commercial aspects of the business. Prior to joining RDD, John held various leadership roles including, President & Chief Operating Officer/Chief Commercial Officer with Melinta Therapeutics, and Senior Vice President of Sales and Managed Markets with Salix Pharmaceuticals. Notably, at Salix Pharmaceuticals (Salix), Mr. Temperato played a critical role in the successful commercialization and growth of their broad GI portfolio and executed over ten launches during his tenure at the company driving growth of company revenues from $119 million in 2004 to $2 billion in 2015, when Salix was acquired by Bausch Health (NYSE: BHC) for ~$16 B. Across his career, John has been instrumental in defining and executing capital efficient go-to-market strategies, business development strategy and overseeing the commercialization and life-cycle management for small molecules, devices, and biologics. Additionally, he has developed strategies for reimbursement and external healthcare policy. John also brings with him extensive financial strategy and investor relations experience.

What is John Temperato's net worth?

The estimated net worth of John Temperato is at least $0.00 as of July 6th, 2022. Mr. Temperato owns 1,427,522 shares of 9 Meters Biopharma stock worth more than $0 as of April 19th. This net worth approximation does not reflect any other investments that Mr. Temperato may own. Learn More about John Temperato's net worth.

How do I contact John Temperato?

The corporate mailing address for Mr. Temperato and other 9 Meters Biopharma executives is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. 9 Meters Biopharma can also be reached via phone at (919) 275-1933 and via email at [email protected]. Learn More on John Temperato's contact information.

Has John Temperato been buying or selling shares of 9 Meters Biopharma?

John Temperato has not been actively trading shares of 9 Meters Biopharma during the past quarter. Most recently, on Wednesday, July 6th, John Temperato bought 125,000 shares of 9 Meters Biopharma stock. The stock was acquired at an average cost of $0.23 per share, with a total value of $28,750.00. Following the completion of the transaction, the chief executive officer now directly owns 1,427,522 shares of the company's stock, valued at $328,330.06. Learn More on John Temperato's trading history.

Who are 9 Meters Biopharma's active insiders?

9 Meters Biopharma's insider roster includes Michael Constantino (Director), Mark Sirgo (Director), Edward Sitar (CFO), and John Temperato (CEO). Learn More on 9 Meters Biopharma's active insiders.

Are insiders buying or selling shares of 9 Meters Biopharma?

In the last twelve months, insiders at the sold shares 1 times. They sold a total of 9,100 shares worth more than $11,011.00. The most recent insider tranaction occured on April, 21st when CFO Bethany Sensenig sold 9,100 shares worth more than $11,011.00. Insiders at 9 Meters Biopharma own 2.4% of the company. Learn More about insider trades at 9 Meters Biopharma.

Information on this page was last updated on 4/21/2023.

John Temperato Insider Trading History at 9 Meters Biopharma

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/6/2022Buy125,000$0.23$28,750.001,427,522View SEC Filing Icon  
3/3/2022Buy100,000$0.56$56,000.00View SEC Filing Icon  
11/18/2021Buy50,000$1.05$52,500.00View SEC Filing Icon  
8/18/2021Buy25,000$1.05$26,250.001,102,522View SEC Filing Icon  
4/5/2021Buy100,000$1.00$100,000.001,077,522View SEC Filing Icon  
8/21/2020Buy70,000$0.69$48,300.00615,496View SEC Filing Icon  
8/17/2020Buy35,000$0.57$19,950.00545,496View SEC Filing Icon  
6/15/2020Buy10,000$0.60$6,000.00
See Full Table

John Temperato Buying and Selling Activity at 9 Meters Biopharma

This chart shows John Temperato's buying and selling at 9 Meters Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

9 Meters Biopharma Company Overview

9 Meters Biopharma logo
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.01
Low: $0.00
High: $0.02

2 Week Range

Now: N/A

Volume

N/A

Average Volume

315,915 shs

Market Capitalization

$1.04 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.36
Strange new buyer driving up gold
From Stansberry Research   |   Ad
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
But there's a much better move you can make to get in front of these big moves today.